Other

Siemens Healthcare Diagnostics Gmbh

Elmar-Reinhold Burchardt

Andreas Knorr

Guido Hennig

Mathias Gehrmann

Werner Kroll

Detlef Schuppan

Thomas Lampe

Christoph Petry

Michael Becka

Michael J Arthur

Massimo Pinzani

Michael Volker

Sylvia Unger

Walter St&ouml;cker

Michael Schauer

Alastair D Burt

Robert P Thiel

William Rosenberg

The invention provides diagnostic methods, kits, and systems, and related computer-readable media, which use multiple blood marker values, including serum and plasma marker values, to aid in the diagnosis of the status or progress of a liver disease in a patient. The invention also provides methods and systems, and related computer-readable media, that use blood marker values, including serum and plasma marker values: (1) to screen for active ingredients useful in the treatment of a liver disease; (2) to aid in the selection of treatment regimens for patients that are predisposed to, or suffer from, liver disease; and (3) to aid in the design of clinical programs useful in monitoring the status or progress of liver disease in one or more patients.

Liver disease-related methods and systems

The present invention concerns a method for diagnosing liver fibrosis wherein two or more diagnostic markers are measured and the measurements are correlated by a mathematic algorithm characterized in that the diagnostic markers are selected from the group N-terminal procollagen III propeptide (PIIINP), Collagen IV, Collagen VI, Tenascin, Laminin, Hyaluronan, MMP-2, TIMP-1 and MMP-9/TIMP-1 complex. The algorithm can be used to predict the histological score of a liver biopsy.

Assessment of liver fibrosis scoring with serum marker algorithms

The invention relates to a method of treating a fibrotic disease, comprising administering to a mammal an effective amount of a phospinate-peptide analog of the general formula (I).

Phosphinate peptide analogs for the treatment of fibrotic disorders

Growing community of inventors

Schwerte, Germany

Elmar-Reinhold Burchardt